

## PAPER DETAILS

TITLE: Roles of Probiotics in Animal Health

AUTHORS: Yigit SEFEROGLU,Sükrü KIRKAN

PAGES: 40-46

ORIGINAL PDF URL: <https://dergipark.org.tr/tr/download/article-file/2201217>



## Roles of Probiotics in Animal Health

Yiğit SEFEROĞLU<sup>1\*</sup> , Şükrü KIRKAN<sup>1</sup> 

<sup>1</sup>Aydın Adnan Menderes University, Faculty of Veterinary Medicine, Department of Microbiology, AYDIN

### ABSTRACT

Probiotics are defined as live microorganisms consumed by humans and animals that affect the intestinal microflora qualitatively or quantitatively or trigger the beneficial effects of the immune system. The discovery of probiotics and the beginning of studies date back to the end of the 19<sup>th</sup> century. Afterwards, these studies continue on the microorganisms used as probiotics, selection criteria and probiotic microorganisms in the animal microbiota. Today's probiotics are used as immune system modulation and protection against pathogenic microorganisms in veterinary medicine. In recent studies against gastrointestinal system disorders in cats, dogs and poultry and on the immune system before or after treatment, probiotic applications have been found to be successful in ruminants, especially in mastitis cases. Due to important problems caused by the use of antibiotics in animal breeding, such as the increase in populations of antibiotic resistant bacteria, it seems possible to use the latest probiotic applications as an alternative to antibiotics, especially for prophylaxis. In this review, the effectiveness of probiotic microorganisms on the basis of diseases and their effects on the immune system are discussed together with current studies.

*Keywords: Animal health, immune system, probiotic*

## Probiyotiklerin Hayvan Sağlığındaki Roller

### ÖZET

Probiyotikler kalitatif veya kantitatif olarak bağırsak mikroflorasına etki eden ya da immün sistemin faydalı etkilerini tetikleyen, insanlar ile hayvanların tükettiği canlı mikroorganizmalar olarak tanımlanmaktadır. Probiyotiklerin keşfi ve çalışmaların başlaması 19. yüzyılın sonlarına dayanmaktadır. Devamında probiyotik olarak kullanılan mikroorganizmalar, seçim kriterleri ve hayvan mikrobiyotasında bulunan probiyotik mikroorganizmalar ile ilgili araştırmalar devam etmektedir. Günümüz veteriner hekimliğinde probiyotikler, immün sistem modülasyonu ve patojen mikroorganizmalara karşı koruyucu olarak kullanılmaktadır. Kedi, köpek, kanatlılarda gastrointestinal sistem rahatsızlıklarına karşı ve tedavi öncesi veya sonrasında immün sistem üzerinde son yıllarda yapılan güncel çalışmalarda ise ruminantlarda özellikle mastitis vakalarında probiyotik uygulamalarının başarılı olduğu görülmüştür. Hayvan yetiştiriciliğinde antibiyotik kullanımının oluşturduğu, başta antibiyotik dirençli bakteri popülasyonlarının artması gibi, önemli sorunlar nedeniyle son probiyotik uygulamalarının özellikle profilaksi amacıyla antibiyotiklere alternatif olarak kullanımı mümkün görülmektedir. Bu derlemede probiyotik mikroorganizmaların hastalıklar bazında etkinliği, immün sistem üzerindeki etkileri güncel çalışmalar ile birlikte ele alınmıştır.

*Anahtar kelimeler: Hayvan sağlığı, immün sistem, probiyotik*

Corresponding author: Yiğit SEFEROĞLU; yigit.seferoglu@adu.edu.tr, Aydın Adnan Menderes University, Faculty of Veterinary Medicine, Department of Microbiology, ORCID: 0000-0002-3033-2634

Received Date: 20.01.2022 – Accepted Date: 01.03.2022

DOI: 10.53913/aduveterinary.1060132

## Introduction

The term probiotic was first used by Lilly and Stillwell in 1965 as “materials secreted by a microorganism that stimulate the proliferation of another microorganism” and the opposite meaning of the term antibiotic (Kaur et al., 2002). Probiotics were defined by Parker in 1974 as additional complementary foods that have beneficial effects on the intestinal microflora. In 1989, Fuller defined probiotics as “live microbial nutritional supplements that improve intestinal microbial balance for the benefit of the host animal” (Sullivan and Nord, 2002).

The first study on probiotics was made in the late 19th century by the Nobel Prize-winning Russian biologist Elie Metchnikoff, known as the father of probiotics. Metchnikoff established a relationship between fermented milk consumption and longevity and detected the presence of probiotics (lactic acid bacteria) in milk. Metchnikoff observed that Bulgarian villagers who ate yoghurt containing *Lactobacillus* as a regular part of their daily meal consumption had significant longevity and theorized that lactic acid bacteria extended their lifespan (Schrezenmeir and Vrese, 2001).

## Microorganisms Used in Probiotics and Selection Criteria

The compound of the gastrointestinal tract flora differs between individuals and within the same individual throughout life. The flora of this system includes both “friendly” and pathogenic bacteria that exist in a complex symbiosis. Many factors such as aging, stress, diet, medication (especially the use of antibacterial), climate, sickness and lifestyle can corrupt this balance, leading to diarrhoea, mucosal inflammation or other serious diseases (Teshale et al., 2017). The pivotal event in the development of a probiotic approach to animal health was the dosing of newly hatched hens with a suspension of gut ingredients designed from healthy adult chickens to detect *Salmonella* spp. in the gut was found to be protected against colonization. Microorganisms used in probiotics include those derived from *Bacillus*, *Enterococcus*, *Streptococcus*, *Clostridium*, *Lactobacillus*, *Bifidobacterium* species and *Escherichia*

*coli* (Kruis et al., 2004). Most probiotic bacteria are lactic acid producing bacteria. Lactic acid has been shown to inhibit coliform growth in the gastrointestinal tract. Acidic flora is harmful to various pathogens. The most widely used probiotic strains include lactic acid bacteria and other Gram-positive bacteria that have been used in food production processes (yogurt, cheese, pickles) for centuries (Henker et al., 2007).

An ideal probiotic should have various potential features that being non-pathogenic and non-toxic by nature, beneficial to the host animal, high viability, stable in storage, capable of surviving or colonizing intestinal tissue, and susceptible for cultivation in an industrial area (Teshale et al., 2017). In addition to these, a probiotic should also have properties stomach acidity, resistance to pancreatic enzymes and bile, ability to adhere to intestinal mucosal cells, high survival rate during transportation during storage, and production of antimicrobial clauses against pathogenic bacteria (Boaventura et al., 2012). In the selection of probiotics, the digestive system of healthy animals or sources of microorganisms such as flowers, rotting fruits and other niches should be selected first. Subsequently, the microorganisms intended to be studied are isolated and identified through selective culture media. A new culture is designed with only target colonies for in vivo evaluation by comparing characteristics such as target species pathogenicity, pathogen inhibition, resistance to host situations. If there are no restrictions on the use of the target species, large and small scale in vivo supplementation experiments are performed to check whether there are real benefits to the host. Finally, probiotics can be produced and used commercially, offering substantial satisfactory results. The main bacteria used in probiotic products were showed in Table 1 (Boaventura et al., 2012). Yeasts are rich in protein, B vitamins, exogenous enzymes and trace elements, and they also have a high degree of digestibility. However, very few yeast species are used commercially. *Saccharomyces cerevisiae*, also known as baker’s yeast, is one of the most common commercialized yeast strains (Vanbelle et al., 1990).

**Table 1.** Bacteria used in probiotic products (Teshale et al., 2017).

Lactobacillus	Bifidobacterium	Other Lactic acid producing bacteria	Non-lactics
<i>L. acidophilus</i>	<i>B. adolescentis</i>	<i>E. faecalis</i>	<i>B. cereus</i>
<i>L. casei</i>	<i>B. animalis</i>	<i>E. faecium</i>	<i>E. coli</i>
<i>L. crispatus</i>	<i>B. bifidum</i>	<i>Sporolactobacillus</i>	<i>P. freudenreichii</i>
<i>L. gallinarum</i>	<i>B. breve</i>	<i>Leuconostoc</i>	
<i>L. gasser</i>	<i>B. infantis</i>	<i>Mesenteroides</i>	
<i>L. johnsonii</i>	<i>B. lactis</i>	<i>S. thermophilus</i>	
<i>L. paracasei</i>	<i>B. longum</i>	<i>P. acidilactici</i>	
<i>L. plantarum</i>			
<i>L. reuteri</i>			
<i>L. rhamnosus</i>			

### Modes of Action of Probiotics

The effect of probiotics was noted only concerning the incidence of the gastrointestinal tract, diarrhea and other intestinal infections (Sullivan and Nord, 2002). However, probiotics general mechanisms of action can be broadly classified as competitive exclusion, bacterial antagonism, and immune modulation (Yirga, 2015).

The competitive exclusion principle is defined as the protective power of normal microflora from the harmful effects of pathogens. This concept is based on the supplementation of the diet of selected cultures of beneficial microorganisms with potentially harmful bacteria for sites of adhesion and organic substrates (main carbon and energy sources). It includes adhesion to the cell wall of the digestive tract, preventing colonization of pathogenic microorganisms or competing for nutrients (Yirga, 2015).

Probiotics show their bactericidal activity effect by fermenting lactose to lactic acid, lowering the pH to a level that harmful bacteria cannot tolerate. In addition to these effects, for example, *Lactobacillus* species produce hydrogen peroxide and some *Enterococcus* species prevent the development of pathogenic microorganisms by producing antimicrobial substances such as nisin (McDonald et al., 2010).

### Use of Probiotics in Animal Health

Nowadays, probiotic additives are among the chemicals that support growth, especially in animals, and studies that increase resistance against diseases in animals are also supported. Probiotics prevent the deterioration of body balance in animals and increase the development of natural healthy microflora (Boaventura et al., 2012). Probiotic preparations are in different forms such as powder, granule, pellet, liquid suspension and capsule and can be used by mixing with drinking water or food. Live bacteria, fungi and yeasts used as probiotics have to maintain their viability during storage, application and in the intestinal environment to show their effects (Krehbiel et al., 2003). Probiotic preparations consisting of *Lactobacillus*, *Bifidobacterium* and *Streptococcus* species should be stored at 22-25 °C and in a dry place. They lose their vitality when the storage temperature rises above 30 °C. In addition, yeast *Saccharomyces cerevisiae* and *Bacillus* spp. can withstand the pelleting temperature, while *Lactobacillus*, *Bifidobacterium* and *Streptococcus* spp. depend on the pelleting temperature, significant losses occur. With the microencapsulation method applied to bacteria used as probiotics recently, these bacteria can be made to withstand the pelleting temperature of 90-95° C (Vanbelle et al., 1990). When studies for dogs and cats were examined, it was determined that there were more microorganisms in their gastrointestinal tract than humans. While *Lactobacillus* species have been detected in all intestinal sections in cats and dogs, it has been reported that there are also species found in humans within these *Lactobacillus* species (Grześkowiak et al., 2015).

Pascher et al. (2008) investigated the impacts of *Lactobacillus acidophilus* DSM 13241 in dogs with non-specific dietary sensitivity. As a result of the study, feeding with probiotics improved stool consistency, stool dry matter, and stool frequency. Numerically less *C. perfringens* and *Escherichia* spp. were detected in the stools of dogs given probiotic than those not given (control group). In addition, it was determined that *Lactobacillus* spp. and *Bifidobacterium* spp. were increased numerically in dogs given probiotics. Sauter et al. (2006) examined by adding two lyophilized *Lactobacillus acidophilus* (NCC2628 and NCC2766) and one lyophilized *Lactobacillus johnsonii* (NCC2667) each strain at a density of 10<sup>10</sup> to their feed for four weeks, in 21 dogs with foodborne diarrhoea. As a result of their study, they found useful impacts on intestinal microbiota and cytokine patterns; the number of enterobacteria in the stool was decreased and the number of *Lactobacillus* spp. increased. Clinical improvement was observed in all dogs treated with probiotics.

Strompfova and Marcinakova (2006) reported that the potential probiotic strain *Lactobacillus fermentum* AD1 isolated from dog feces had high survival (86.54%) at pH 3 in in vitro study and a high adhesion ability to the intestinal layer. *Lactobacillus fermentum* AD1 strain at 10<sup>9</sup>/ml was given to the diet of 15 healthy dogs for seven days. As a result of the research, the number of *Lactobacillus* spp. and *Enterococcus* spp. in the stool was significantly increased.

In a study on probiotic efficacy in dogs with inflammatory bowel disease, twenty dogs were treated with probiotic (a mixture of strains belonging to species *Lactobacillus casei*, *Lactobacillus plantarum*, *Lactobacillus delbrueckii subspecies bulgaricus*, *Lactobacillus acidophilus*, *Bifidobacterium longum*, *B. breve*, *B. infantis*, and *Streptococcus salivarius subspecies thermophilus*) for 60 days. As a result of these applications, the protective effect of the probiotic significantly reduced CD3 + T cell infiltration as well as positive clinical and histological findings. They also found a normalization of intestinal dysbiosis in dogs treated with probiotics. The result of this study shows that the probiotics used in the treatment of inflammatory bowel disease in dogs can be successful and more research is needed in the field of probiotics and infectious bowel disease (Jergens and Simpsons, 2012). Strompfova et al. (2014) determined that it increased the amount of organic acid in the blood serum of dogs and decreased the amount of triglyceride and albumin in the study they conducted with *Bifidobacterium animalis* B/12 strain (10<sup>9</sup> CFU) of canine origin. In addition, they found an increase in the phagocytic activity of leukocytes. Grześkowiak et al. (2014) found that *Lactobacillus plantarum* VET14A, *Lactobacillus rhamnosus* VET16A, *Lactobacillus fermentum* VET9A strains isolated from dogs showed successful adhesion to the enteric mucosa. Besides, they stated that it prevents the colonization of widespread enteropathogens such as *Clostridium perfringens*, *Salmonella enterica* serovar *Typhimurium*, *Enterococcus canis*, in their in vitro studies.

The probiotic product containing *E. faecium* SF68 increased immune responses to vaccination in puppies and kittens eight to 52 weeks old and seven to 27 weeks old, respectively. Vaccine applications were applied in the first and fourth weeks of the study. An increase in IgA content can be interpreted as a sign of enhanced protection against pathogens. However, increased IgA concentrations may represent a response to antigenic stimulation without increased immunity or to the body's protective mechanism against a noxious stimulus (Veir et al., 2007). *Lactobacillus rhamnosus* GG probiotic strain has many immunomodulatory effects, such as its use as an adjuvant in allergic diseases and vaccines, as well as its effects on gastrointestinal health, especially in newborns (Segers and Lebeer, 2014). In a study conducted to evaluate puppies sensitive to *Dermatophagoides farinae*, those not given probiotics were formed as a control group, and those given *Lactobacillus rhamnosus* GG, which is used to reduce allergic symptoms, were formed as an experimental group. The experimental group was given probiotics containing *Lactobacillus rhamnosus* GG from three weeks to six months. All puppies used in the study were found to be susceptible to *D. farinae*. In the intradermal skin tests of the experimental group using probiotics, lower reaction rates and lower IgE titers were detected in the control group. Since all dogs were sensitive, they were followed and the favourable effect was observed three years after the truncation of the probiotic treatment (Marsella, 2009).

Durand et al. (2006) stated that the number of *Escherichia coli* O157:H7 was considerably reduced by the application of a probiotic preparation containing *Lactobacillus fermentum*, *Streptococcus faecium*, *L. plantarum*, *L. acidophilus* and *L. casei* in sheep feces.

Lema et al. (2001) researched the influence of *Lactobacillus acidophilus*, *Streptococcus faecium*, a blend of *Streptococcus faecium*, *Lactobacillus acidophilus* and a mixture of *Lactobacillus casei*, *L. acidophilus*, *S. faecium*, *L. plantarum* and *L. fermentum* in reducing fecal shedding of sheep experimentally infected with *Escherichia coli* O157:H7. As a result of the research, they found that dietary *S. faecium* decreased the fecal shedding of *E. coli* O157:H7. Ohya et al. (2000) investigated the effect of two probiotic bacteria (*Streptococcus bovis* LCB6, *Lactobacillus gallinarum* LCB12) isolated from healthy calves on faecal shedding in calves experimentally infected with *Escherichia coli* O157:H7. As a result of the study, they reported that the treatment of cattle with the probiotics was shown to eliminate fecal shedding of *Escherichia coli* O157:H7 in experimentally infected calves compared to the control group. Mazmanian et al. (2005) reported that polysaccharides produced by *Bacteroides fragilis* in ruminants and some mammals play various immunomodulatory roles in directing maturation of the developing immune system, including correcting systemic T cell deficits, regulating helper T cell 1 and T cell 2 derangements and directing lymphoid tissue biogenesis. A recent study by Donaldson et al. (2018) found that the immunoglobulin A antibody

produced by the host in response to the *Bacteroides fragilis* capsule provides a colonization advantage by helping the bacteria bind to the epithelial surface.

The use of probiotics in the dairy industry to treat mastitis of ruminants, especially cattle, is also widely studied and researched. *Lactococcus lactis* DPC 3147 with broad-spectrum antimicrobial properties has been reported to be successful in its activity against pathogens causing mastitis in in vitro studies. When combined with a bismuth-based product, *Lactococcus lactis* DPC 3147 has been found to have a protective effect in cases of mastitis caused by *Staphylococcus aureus* and *Streptococcus dysgalactiae*, which are frequently seen in dried cows (Hu et al., 2019). Klostermann et al. (2008), compared intramammary *Lactococcus lactis* DPC 3147 and antibiotic administration in naturally infected cows with subclinical and clinical mastitis. In antibiotic treatment, prednisolone was used together with amoxicillin-clavulanic acid, which was found to be sensitive to the bacterial agent. Nine out of 25 animals treated with intramammary antibiotics and seven out of 25 animals treated with intramammary live *Lactococcus lactis* DPC 3147 had a similar bacteriological profile at the end of the 12th day. There was no change in the number of somatic cells in the two experimental groups compared to the previous ones. At the end of the research, 15 animals out of 25 treated with *Lactococcus lactis* DPC 3147 and 18 animals out of 25 treated with antibiotics did not show clinical signs of the disease after treatment. According to the research results, they reported that *Lactococcus lactis* DPC 3147 showed that mastitis treatment was possible and that it could be as effective as common antibiotic treatments in some cases. Armas et al. (2017) investigated in vitro the antagonist activity adhesion and invasion ability of *Lactococcus subsp. lactis* LMG 7930 nisin-producing strain. As a result of the study, they found successful in terms of invasion and adhesion to the cow mammary epithelial cell line. They reported that *Lactococcus subsp. lactis* LMG 7930 as an antagonistic effect inhibited two strains of cow mastitis, *S. aureus* LMG 16805 and *Streptococcus agalactiae* LMG 14838. It failed to inhibit *Escherichia coli* 285-05, *Staphylococcus intermedius* 146-08 and *Streptococcus dysgalactiae* 115-06, *Streptococcus agalactiae* 115-06, *S. aureus* 357-08, *S. epidermidis* 175-07, *S. epidermidis* 200-SA, *S. chromogenes* 100-SA, *Lactococcus cremoris* LMG 7951 strains in sheep.

Pellegrino et al. (2019) 12 probiotic bacteria isolated from milk samples (*Pediococcus pentasaccharicus* CRL 1831, *P. pentasaccharicus* CRL 1832, *Weissella cibaria* CRL 1833, *W. cibaria* CRL 1840, *Enterococcus hirae* 7-3, *E. hirae* CRL 1834, *E. hirae* CRL 1835, *E. hirae* CRL 1837, *E. mundii* CRL 1656, *Lactococcus lactis* CRL 1655, *L. perolens* CRL 724, *L. plantarum* CRL 1716) and evaluated their antimicrobial effects against selected mastitis agents. *S. aureus* ATCC25923, *S. aureus* RC108, *S. epidermidis* ATCC14990, *S. agalactiae* ATCC27956, *S. dysgalactiae* ATCC27957, *S. uberis* 102, *S. uberis* ATCC27958, *S. hyicus* 112249, *S. bovis* ATCC27960, *Enterococcus faecalis* 1943, *E. faecium*

35667, *Pseudomonas* spp., *Escherichia coli* 345, *E. coli* ATCC35218 and *K. pneumoniae* ATCC10031 were selected as mastitis agents. They rated the antimicrobial effects of bacteria isolated from milk against selected mastitis agents at low, medium and high levels. As a result of the research, it was determined that *L. plantarum* CRL 1716 did not show any antimicrobial activity against mastitis agents except *S. dysgalactiae* ATCC27957, *E. coli* 345, *E. coli* ATCC35218, *Pseudomonas* spp. and *K. pneumoniae* ATCC10031. *Lactococcus lactis* CRL 1655 *E. hirae* CRL 1835, *E. hirae* CRL 1837, *E. mundii* CRL 1656 showed high, other probiotic bacteria showed moderate antimicrobial activity against *S. dysgalactiae* ATCC27957. Antimicrobial activity of all probiotic bacteria isolated from milk against *S. dysgalactiae* ATCC 27957 was the most striking result in this study.

Microorganisms in balance in the gastrointestinal tract of a healthy poultry aid digestion and absorption and increase body resistance against infectious diseases. This balance is disrupted due to stress or illness. In such cases, changes occur in the intestinal flora and thus the balance of the flora is disturbed. The number of lactic acid bacteria in the flora decreases also number of pathogenic bacteria may increase (Koçak et al., 2016). Wang et al. (2017) reported that feeds containing *Bacillus* spp. were more effective in feed conversion rate and body weight gain rate in poultry. They also stated that the intense presence of *Firmicutes* species increased the accumulation of acetate in the cecum and the application of *Lactobacillus casei* in broiler chickens was beneficial for the health and development of chickens by reducing the urease activity in the ileum.

Torshizi et al. (2010) stated that the incidence of Salmonellosis in broilers decreased significantly when a commercial product containing *Lactobacillus casei*, *L. acidophilus*, *Enterococcus faecium* and *Bifidobacterium bifidum* was given together with feed or drinking water. In the same study, they found that there was a significant improvement in the experimental groups compared to the control groups in terms of body weight and feed conversion rates on the 31st day. Kergourlay et al. (2012) reported the draft genome sequence of *Lactobacillus salivarius* SMXD51 isolated from the cecum of healthy chickens, showing activity against *Campylobacter jejuni*, the most common cause of Campylobacteriosis infection. As a result of the study, they determined that *Lactobacillus salivarius* SMXD51 has interesting properties as a potential probiotic strain. Santini et al. (2010) investigated the antimicrobial activity of 55 isolates (lactic acid producing bacteria and Bifidobacterium species) against *Campylobacter jejuni* LMG 8842, *C. jejuni* CIP70.2, and *C. jejuni* 221/05 strains. As a result of the study, they determined that *Bifidobacterium longum subspecies longum* PCB 148, *B. longum subsp. longum* PCB 133, *B. breve* PCB 110, *B. pseudocatenulatum* PCB 107, *B. longum subsp. infantis* PCD 889B, *B. thermophilum* PCD 359B, *B. longum subsp. longum* PCD 232B, *L. plantarum* PCS 20, *Lactobacillus* spp. PCK 161, *L. pseudomesenteroides*

PCK 18, *L. plantarum* PCA 306, *L. plantarum* PCA 293, *L. plantarum* PCA 275, *L. plantarum* PCA 259, *L. plantarum* PCA 236, *L. pentosus* PCA 227 showed antimicrobial activity against three of the *C. jejuni* LMG 8842, *C. jejuni* CIP70.2 and *C. jejuni* 221/05 strains. Elraheam Elsayed et al. (2021) investigated the beneficial effects of a potential synbiotic (*Lactobacillus delbrueckii subspecies bulgaricus*, *L. plantarum*, *L. acidophilus*, *L. rhamnosus*, *B. bifidum*, *E. faecium*, *S. thermophilus*, *Aspergillus oryzae*, *Candida pintolepesii*) with a concentration of  $2 \times 10^9$  cfu/g, commercial product (%90 lactic acid, %10 formic acid) and multi-strain bacterin formulated from avian pathogenic multidrug-resistant *Escherichia coli* O26, O78, *S. Enteritidis* and *S. Typhimurium* serotypes. They performed a challenge test against *E. coli* O26, O78, *S. Enteritidis* and *S. Typhimurium* after eight days of using that three products together or alone. As a result of the study it was determined the combined use of that three products, especially when applied on the first day, mortality, developed erythrogram parameters, produced the immunomodulatory effect, decreased proinflammatory cytokine levels and enhanced growth performance parameters. Talebi et al. (2014) investigated the antibody response of the probiotic commercial product (*L. acidophilus*, *L. casei*, *E. faecium*, *B. bifidum*) to the Newcastle and Gumboro vaccine. In both vaccine administrations, maternal antibodies decreased to normal levels by 21 days, but the decrease in titer was slower in the probiotic-treated groups than in the vaccinated or control groups. Stefaniak et al. (2020) investigated the early in ovo administration (on day 12 of embryo incubation) of selected synbiotics in broilers that affects the humoral immune response to experimental antigens. They found that the in ovo application of synbiotic (inulin and *Lactococcus lactis subsp. Lactis*) did not significantly influence the humoral immune response against T cell-dependent antigen and IgG value. However at the end of the 35 days, they reported that the while mortality rate was 8.5% in the control group, it was 2.1% in the synbiotic-administered experimental group. Wu et al. (2019) investigated the impacts of *Enterococcus faecium* NCIMB 11181 on the growth performance and immune reaction of broilers. They found an increase in growth and antibody response at the rates of  $1 \times 10^8$  and  $2 \times 10^8$  CFU/kg added to the daily feed of the broilers, but they determined the highest amount of IgG in the serum on the 35th day in the other experimental group at the rate of  $5 \times 10^7$  CFU/kg. Koenen et al. (2004) reported that chickens fed diets containing liquid Lactobacillus induced higher IgG and IgM responses compared to the others. In a different study, Huang et al. (2004) stated that when they applied *Lactobacillus acidophilus* and *Lactobacillus casei* in the feed they consumed daily, they detected a higher IgA response compared to the control group, while the IgG value was not affected.

## Conclusion

Probiotic applications are at the forefront of the methods applied in recent years due to important problems

caused by the use of antibiotics in animal husbandry, such as the increase in populations of antibiotic resistant bacteria. Although probiotics are not expected to replace antibiotics in the treatment of an acute disease, it seems possible to use them as an alternative to antibiotics for prophylaxis and growth performance in animals. In recent years, studies on probiotics in ruminants have been conducted in mastitis cases and have shown that intramammary applications can be as effective as antibiotics.

The impacts of probiotics, prebiotics and synbiotics on the immune system and its components have been seen positive in some studies on cats and dogs and poultry, and it has been concluded that longer-term evaluation is required in scientific studies to see their effects in other species.

### Acknowledgements

This review article was prepared from the first doctoral seminar of the corresponding author.

### Conflict of interest

The authors declare that they have no conflict of interest in this study.

### References

- Armas, F., Camperio, C., Marianelli, C. (2017). In Vitro Assessment of the Probiotic Potential of *Lactococcus lactis* LMG 7930 against Ruminant Mastitis-Causing Pathogens. *PLOS ONE*, 12(1), Article e0169543 1-13. <https://doi.org/10.1371/journal.pone.0169543>
- Boaventura, C., Rafael, A., Ana, U., Jacques, N., Luis, G. (2012). The Benefits of Probiotics in Human and Animal Nutrition. *NAB Clinical Gastroenterology*. IntechOpen, 75-100. 10.5772/34027
- Donaldson, G.P., Ladinsky, M.S., Yu, K.B., Sanders, J.G., Yoo, B.B., Chou, W.C., Conner, M.E., Earl, A.M., Knight, R., Bjorkman, P.J., Mazmanian, S.K. (2018). Gut microbiota utilize immunoglobulin A for mucosal colonization. *Science*, 360(6390), 795–800. 10.1126/science.aag0926
- Durand, F.C., Madic, J., Doudin, F., Martin, C. (2006). Biotic and abiotic factors influencing in vitro growth of *Escherichia coli* O157:H7 in ruminant digestive contents. *Applied and Environmental Microbiology*, 72(6), 4136–4142. 10.1128/AEM.02600-05
- Elaheam Elsayed, M.S.A., Shehata, A.A., Ammar A.M., Allam, T.S., Ali, A.S., Ahmed, R.H., Muhammed, A.A., Tarabees, R. (2021). The beneficial effects of a multistrain potential probiotic, formic, and lactic acids with different vaccination regimens on broiler chickens challenged with multidrug-resistant *Escherichia coli* and *Salmonella*. *Saudi Journal of Biological Sciences*, 28(5), 2850–2857. 10.1016/j.sjbs.2021.02.017
- Grześkowiak, L., Collado, M.C., Beasley, S., Salminen, S. (2014). Pathogen exclusion properties of canine probiotics are influenced by the growth media and physical treatments simulating industrial processes. *Journal of Applied Microbiology*, 116(5), 1308–1314. 10.1111/jam.12477
- Grześkowiak, L., Endo, A., Beasley, S., Salminen, S. (2015). Microbiota and probiotics in canine and feline welfare. *Anaerobe*, 34, 14–23. <http://dx.doi.org/10.1016/j.anaerobe.2015.04.002>
- Henker, J., Laass, M., Blokhin, B.M., Bolbot, Y.K., Maydannik, V.G., Elze, M., Wolff, C., Schulze, J. (2007). The probiotic *Escherichia coli* strain Nissle 1917 (EcN) stops acute diarrhea in infants and toddlers. *European Journal of Pediatrics*, 166(4), 311–318. 10.1007/s00431-007-0419-x
- Hu, X., Li, S., Fu, Y., Zhang, N. (2019). Targeting gut microbiota as a possible therapy for mastitis. *European Journal of Clinical Microbiology & Infectious Diseases*, 38(8), 1409–1423. 10.1007/s10096-019-03549-4
- Huang, M.K., Choi, Y.J., Houde, R., Lee, J.W., Lee, B., Zhao, X. (2004). Effects of *Lactobacilli* and an acidophilic fungus on the production performance and immune responses in broiler chickens. *Poultry Science*, 83(5), 788–795. 10.1093/ps/83.5.788
- Jergens, A.E., Simpson, K.W. (2012). Inflammatory bowel disease in veterinary medicine, *Front Biosci (Elite Ed.)*, 4, 1404–1419. 10.2741/470
- Kaur, I.P., Chopra, K., Saini, A. (2002). Probiotics: potential pharmaceutical applications. *European Journal of Pharmaceutical Sciences*, 15(1), 1–9. 10.1016/s0928-0987(01)00209-3
- Kergourlay, G., Messaoudi, S., Dousset, X., Prevost, H. (2012). Genomesequencing of *Lactobacillus salivarius* SMXD51, a potential probiotic strain isolated from chicken cecum, showing anti-campylobacter activity. *Journal of Bacteriology*, 194(11), 3008–3009. 10.1128/JB.00344-12
- Klostermann, K., Crispie, F., Flynn, J., Ross, R.P., Hill, C., Meaney, W. (2008). Intramammary infusion of a live culture of *Lactococcus lactis* for treatment of bovine mastitis: comparison 44 with antibiotic treatment in field trials. *Journal of Dairy Research*, 75(3), 365–373. 10.1017/S0022029908003373
- Koçak, Y., Fındık, A., Çiftçi, A. (2016). Probiyotikler: Genel özellikleri ve güvenilirlikleri. *Etlik Veteriner Mikrobiyoloji Dergisi*, 27(2), 118–122. 10.35864/evmd.515965
- Koenen, M.E., Kramer, J., van der Hulst, R., Heres, L., Jeurissen, S.H.M., Boersma, W.J.A. (2004). Immunomodulation by probiotic *Lactobacilli* in layer- and meat-type chickens. *British Poultry Science*, 45(3), 355–366. 10.1080/00071660410001730851
- Krehbiel, C.R., Rust, S.R., Zhang, G., Gilliland, S.E. (2003). Bacterial direct-fed microbials in ruminant diets: Performance response and mode of action. *Journal of Animal Science*, 81(2), 120–132. 10.2527/2003.8114\_SUPPL\_2E120X
- Kruis, W., Fric, P., Pokrotnieks, J., Lukas, M., Fixa, B., Kascak, M., Kamm, M.A., Weismueller, J., Beglinger, C., Stolte, M., Wolff, C., Schulze, J. (2004). Maintaining remission of ulcerative colitis with the probiotic *E. coli* Nissle 1917 is as effective as with standard mesalazine. *Gut*, 53(11), 1617–1623. 10.1136/gut.2003.037747
- Lema, M., Rao, D.R., Williams, L. (2001). Reduction of fecal shedding of enterohemorrhagic *Escherichia coli* O157:H7 in lambs by feeding microbial feed supplement. *Small Ruminant Research*, 39(1), 31–39. 10.1016/s0921-4488(00)00168-1
- Marsella, R. (2009). Evaluation of *Lactobacillus rhamnosus* strain GG for the prevention of atopic dermatitis in dogs. *American Journal of Veterinary Research*, 70(6), 735–740. 10.2460/ajvr.70.6.735
- Mazmanian, S.K., Liu, C.H., Tzianabos, A.O., Kasper, D.L. (2005). An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. *Cell*, 122(1), 107–118. 10.1016/j.cell.2005.05.007
- McDonald, P., Edwards, R.A., Greenhalgh, J.F.D., Morgan, C.A., Sinclair, L.A., Wilkinson, R. (2010). *Animal Nutrition* (7th ed.). Harlow: Pearson Books.
- Ohya, T., Marubashi, T., Ito, H. (2000). Significance of fecal volatile fatty acids in shedding of *Escherichia coli* O157 from calves: experimental infection and preliminary use of a probiotic product. *Journal of Veterinary Medical Science*, 62(11), 1151–1155. 10.1292/jvms.62.1151
- Pascher, M., Hellweg, P., Khol-Parisini, A., Zentek, J. (2008). Effects of a probiotic *Lactobacillus acidophilus* strain on feed tolerance in dogs with non-specific dietary sensitivity. *Archives of Animal Nutrition*, 62(2), 107–116. 10.1080/17450390801892583
- Pellegrino, M.S., Frola, I.D., Natanael, B., Gobelli, D., Nader-Macias, M.E.F., Bogni, C.I. (2019). In Vitro Characterization of Lactic Acid Bacteria Isolated from Bovine Milk as Potential Probiotic Strains to Prevent Bovine Mastitis. *Probiotics and Antimicrobial Proteins*, 11(1), 74–84. 10.1007/s12602-017-9383-6
- Santini, C., Baffoni, L., Gaggia, F., Granata, M., Gasbarri, R., Di Gioia, D., Biavati, B. (2010). Characterization of probiotic strains: an application as feed additives in poultry against *Campylobacter jejuni*. *International Journal of Food Microbiology*, 141(1), 98–108. 10.1016/j.ijfoodmicro.2010.03.039

- Sauter, S.N., Benyacoub, J., Allenspach, K., Gaschen, F., Ontsouka, E., Reuteler, G., Cavadini, C., Knorr, R., Blum, J.W. (2006). Effects of probiotic bacteria in dogs with food responsive diarrhoea treated with an elimination diet. *Journal of Animal Physiology and Animal Nutrition*, 90(7-8), 269-277. 10.1111/j.1439-0396.2005.00595.x.
- Schrezenmeir, J., Vrese, M. (2001). Probiotics, prebiotics, and synbiotics-approaching a definition. *The American Journal of Clinical Nutrition*, 73(2), 361-364. 10.1093/ajcn/73.2.361s
- Segers, M.E., Lebeer, S. (2014). Towards a better understanding of *L. rhamnosus* GG - host interactions. *Microbial Cell Factories*, 13(1), 9-16. 10.1186/1475-2859-13-S1-S7
- Stefaniak, T., Madej, J.P., Graczyk, S., Siwek, M., Lukaszewicz, E., Kowalczy, A., Sienczyk, M., Maiorano, G., Bednarczyk, M. (2020). Impact of Prebiotics and Synbiotics Administered in ovo on the Immune Response against Experimental Antigens in Chicken Broilers. *Animals*, 10(4), 643. 10.3390/ani10040643
- Strompfova, V., Marcinakova, M. (2006). Application of potential probiotic *Lactobacillus fermentum* AD1 strain in healthy dogs, *Anaerobe*, 12, 75-79. 10.1016/j.anaerobe.2005.12.001.
- Strompfova, V., Simonová, M.P., Gancarčíková, S., Mudroňová, D., Farbáková, J., Maďari, A., Lauková, A. (2014). Effect of *Bifidobacterium animalis* B/12 administration in healthy dogs. *Anaerobe*, 28, 1-7. 10.1016/j.anaerobe.2014.05.001
- Sullivan, A., Nord, C.E. (2002). The place of probiotics in human intestinal infections. *International Journal of Antimicrobial Agents*, 20(5), 313-319. 10.1016/s0924-8579(02)00199-1
- Talebi, A., Amirzadeh, B., Mokhtari, B., Gahri, H. (2014). Effects of a multi-strain probiotic (PrimaLac) on performance and antibody responses to Newcastle disease virus and infectious bursal disease virus vaccination in broiler chickens. *Avian Pathology*, 37(5), 509-512. 10.1080/0307945080235699
- Teshale, A., Tilahun, A., Hadush, T., Haile, B., Andualem Desta, M. (2017). Bacterial
- Probiotics their Importances and Limitations: A Review. *Journal of Nutrition and Health Sciences*, 4(2), 1-8. 10.15744/2393-9060.4.202
- Torshizi, M.A.K., Moghaddam, A.R., Rahimi, S., Mojgani, N. (2010). Assessing the effect of administering probiotics in water or as a feed supplement on broiler performance and immune response. *British Poultry Science*, 51(2), 178-184. 10.1080/00071661003753756
- Vanbelle, N., Teller, E., Focant, M. (1990). Probiotics in animal nutrition: a review. *Archives Animal Nutrition*, 40(7), 543-567. 10.1080/17450399009428406
- Veir, J.K., Knorr, R., Cavadini, C., Scherrill, S.J., Benyacoub, J., Satyaraj, E., Lappin, M.R. (2007). Effect of supplementation with *Enterococcus faecium* (SF68) on immune functions in cats. *Veterinary Therapeutics*, 8(4), 229-238.
- Wang, Y., Sun, J., Zhong, H., Li, N., Xu, H., Zhu, Q., Liu, Y. (2017). Effect of probiotics on the meat flavour and gut microbiota of chicken. *Scientific Reports*, 7(1), 6400. 10.1038/s41598-017-06677-z
- Wu, Y., Zhen, W., Geng, Y., Wang, Z., Guo, Y. (2019). Effects of dietary *Enterococcus faecium* NCIMB 11181 supplementation on growth performance and cellular and humoral immune responses in broiler chickens. *Poultry Science*, 98(1), 150-163. 10.3382/ps/pey368
- Yirga, H. (2015). The Use of Probiotics in Animal Nutrition. *Journal of Probiotics & Health*, 3(2), 1-10. 10.4172/2329-8901.1000132